Dabigatran: The anticoagulant we have long expected?

Recent Patents on Cardiovascular Drug Discovery

Volumn 5, Issue 3, 2010, Pages 223-226

  Tagarakis, Georgios I ^a   Karangelis, Dimos ^a   Daskalopoulos, Marios E ^a   Tsilimingas, Nikolaos B ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Anticoagulant ; Dabigatran; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; CLARITHROMYCIN; CYCLOSPORIN; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; ESOMEPRAZOLE; GARLIC EXTRACT; GINGER EXTRACT; IBUPROFEN; LANSOPRAZOLE; MACROLIDE; METRONIDAZOLE; MIFEPRISTONE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PRADAX; PROTAMINE SULFATE; QUINIDINE; RIFAMPICIN; RITONAVIR; UNCLASSIFIED DRUG; VERAPAMIL; VITAMIN K GROUP; WARFARIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; DIARRHEA; DRUG INDICATION; DRUG SAFETY; DYSPEPSIA; FATIGUE; HUMAN; NAUSEA; OSTEOPOROSIS; PATENT; PHARMACODYNAMICS; PRIORITY JOURNAL; SKIN DISEASE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; VENOUS THROMBOEMBOLISM;

EID: 78649982650     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489010793351926     Document Type: Article

References (36)

1. Camm AJ. The RE-LY study: Randomized evaluation of longterm anticoagulant therapy: Dabigatran vs. warfarin. Eur Heart J 2009; 30(21): 2554-5.
2. Schulman S, Kearon C, Kakkar AK. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361(24): 2342-52.
3. Squizzato A, Dentali F, Steidl L, Ageno W. New direct thrombin inhibitors. Intern Emerg Med 2009; 4(6): 455-7.
4. European Medicinal Agency/European Commission Pradaxa Approval 2008.
5. Canadian National Institute for Health and Clinical Excellence- Pradax Approval 2008.
6. Jirman, J., Richter, J., Lustig, P. A method for the preparation of dabigatran. WO2009111997 (2009).
7. Sinha, U., Hollenbach, S.J., Andre, P. Combination anticoagulant therapy with compound that acts as a factor Xa inhibitor. US20080254036 (2008).
8. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45: 1757-66.
9. Mismetti P, Laporte S. Dabigatran: Clinical pharmacology. Ann Fr Anesth Reanim 2009; 28(9 Suppl): S8-14.
10. Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008; 48(12): 1411-9.
11. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555-63.
12. Trocóniz IF, Tillmann C, Liesenfeld KH, Schäfer HG, Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol 2007; 47: 371-82.
13. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 204S-33S.
14. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115(1): 15-20.
15. Samama MM, Gerotziafas GT. Newer anticoagulants in 2009. J Thromb Thrombolysis 2010; 29(1): 92-104.
16. Stangier J, Rathgen K, Staehle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynmics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
17. Sorbera LA, Bozza J, Castaner J. Dabigatran/dabigatran etexilate: Prevention of DVT, prevention of ischemic stroke, thrombin inhibitor. Drugs Future 2005; 30: 877-85.
18. Samama M, Depasse F. From old to new anticoagulants: The role of the biologist. Ann Biol Clin (Paris) 2009; 67(5): 525-34.
19. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103(6): 1116-27.
20. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. RELY Dabigatran versus warfarin in patients with atrial fibrillation steering committee and investigators. N Engl J Med 2009; 361(12): 1139-51.
21. Baines OJP, Grana CE, Botella JA, García VI. Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban. Farm Hosp 2009; 33(3): 125-33.
22. Mismetti P, Laporte S. Dabigatran: Clinical pharmacology. Ann Fr Anesth Reanim 2009; 28(9 Supp l): S8-14.
23. Connolly SJ, Ezekowitz MD, Yusuf S. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139-51.
24. Eriksson BI, Dahl OE, Rosencher N. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5(11): 2178-85.
25. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, Francis CS, Friedman RJ, et al. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24(1): 1-9.
26. Fuji T, Fujita S, Ujihira T, Sato T. Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients, with a safety profile comparable to placebo. J Arthroplasty 2009 [Epub ahead of print].
27. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370(9591): 949-56. Erratum in: Lancet 2007; 370 (9604): 2004.
28. Dahl OE. Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement: Rationale for dose regimen. Clin Appl Thromb Hemost 2009; 15(Suppl 1): 17S-24S.
29. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100(9):1419-26.
30. Eriksson BI, Dahl OE, Ahnfelt L, Kälebo P, Stangier J, Nehmiz G, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004; 2(9):1573-80.
31. Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. Thromb Haemost 2010; 103(2): 360-71.
32. Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA, et al. Economic evaluation of dabigatran etexilate for the preventionof venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. Thromb Haemost 2010; 103(2): 360-71.
33. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal. Health Technol Assess 2009; 13 (Suppl 2): 55-62.
34. [Hankey GJ. Replacing aspirin and warfarin for secondary stroke prevention: Is it worth the costs? Curr Opin Neurol 2010; 23(1): 65-72.
35. Gage BF. Can we rely on RELY? N Engl J Med 2009; 361(12): 1200-2.
36. Hull RD. Oral Antithrombotic inhibitors: Dabigatran etexilate, meeting an unmet need? Clin Appl Thromb Hemost 2009 [Epub ahead of print].